DaVita Inc. (NYSE:DVA) Shares Bought by Hsbc Holdings PLC

Hsbc Holdings PLC grew its stake in shares of DaVita Inc. (NYSE:DVA - Free Report) by 110.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 153,838 shares of the company's stock after purchasing an additional 80,750 shares during the quarter. Hsbc Holdings PLC owned 0.19% of DaVita worth $23,012,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of DVA. United Capital Financial Advisors LLC grew its stake in shares of DaVita by 2.6% during the fourth quarter. United Capital Financial Advisors LLC now owns 2,416 shares of the company's stock valued at $361,000 after acquiring an additional 62 shares in the last quarter. Freedom Investment Management Inc. raised its holdings in DaVita by 3.6% in the fourth quarter. Freedom Investment Management Inc. now owns 1,790 shares of the company's stock valued at $268,000 after acquiring an additional 62 shares in the last quarter. Exchange Traded Concepts LLC boosted its stake in DaVita by 8.3% during the 4th quarter. Exchange Traded Concepts LLC now owns 891 shares of the company's stock valued at $133,000 after acquiring an additional 68 shares during the last quarter. Impact Partnership Wealth LLC grew its holdings in DaVita by 3.7% during the 4th quarter. Impact Partnership Wealth LLC now owns 1,941 shares of the company's stock worth $290,000 after acquiring an additional 70 shares in the last quarter. Finally, Contravisory Investment Management Inc. raised its stake in shares of DaVita by 1.2% in the 4th quarter. Contravisory Investment Management Inc. now owns 6,082 shares of the company's stock valued at $910,000 after purchasing an additional 73 shares in the last quarter. Hedge funds and other institutional investors own 90.12% of the company's stock.

Analyst Upgrades and Downgrades

DVA has been the subject of a number of research reports. Barclays lifted their price target on DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research note on Tuesday, February 18th. Cowen reissued a "hold" rating on shares of DaVita in a research report on Tuesday, February 18th. StockNews.com upgraded shares of DaVita from a "hold" rating to a "buy" rating in a research note on Friday, April 25th. Finally, Sanford C. Bernstein set a $184.00 price target on shares of DaVita in a report on Friday, February 21st. One analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $166.33.

DaVita Stock Performance

Shares of DVA traded down $0.04 during midday trading on Friday, hitting $140.40. 160,383 shares of the stock traded hands, compared to its average volume of 833,804. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26. DaVita Inc. has a 1-year low of $131.27 and a 1-year high of $179.60. The business's 50 day moving average price is $146.09 and its two-hundred day moving average price is $154.77. The firm has a market capitalization of $11.23 billion, a PE ratio of 13.07, a price-to-earnings-growth ratio of 1.07 and a beta of 1.04.

DaVita (NYSE:DVA - Get Free Report) last posted its earnings results on Thursday, February 13th. The company reported $2.24 EPS for the quarter, topping the consensus estimate of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. Equities research analysts predict that DaVita Inc. will post 10.76 EPS for the current fiscal year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.